GenKyoTex S.A. Collaborators Elucidate Role of NOX4 in Osteoporosis

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

GENEVA & ARCHAMPS, France--(BUSINESS WIRE)--Genkyotex, the leading developer of NOX enzyme inhibitors, announced today that a group of collaborators have discovered a link between the enzyme NOX4 and development of osteoporosis. These results, published online in the Journal of Clinical Investigation doi:10.1172/JCI67603), indicate that inhibitors of NOX4, such as GKT137831 developed by Genkyotex could lead to a novel way of treating patients with osteoporosis. GKT137831, the first in class NOX1 and 4 inhibitor, has shown favorable safety and pharmacokinetic profiles in Phase I studies, and following a recently FDA approved IND will enter a Phase II trial in patients with diabetic nephropathy.

Help employers find you! Check out all the jobs and post your resume.

Back to news